The worldwide dash to get goods to the U.S. ahead of President Trump's tariffs has been distorting trade patterns all year.

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

Last year, the Biden administration set limits on PFAS in drinking water systems. Donald Trump’s EPA is planning to ...

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

Eli Lilly is pumping iron in the GLP-1 prescription ring, gaining muscle with a 52.4% market share and a beefy $1,100 target.

COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

Recent health briefs reveal significant developments in the pharmaceutical sector. Key highlights include Trump's order ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...